From Biotech Daily:
Today, Imugene executive chair Paul Hopper told Biotech Daily that “the situation had changed” and the company would source pembrolizumab elsewhere.Mr Hopper said the trial was “still full speed ahead” and the costs of the drug were not material.
Ann: Pause in Trading, page-75
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.0¢ |
Change
0.001(1.69%) |
Mkt cap ! $439.1M | |||
| Open | High | Low | Value | Volume |
| 6.0¢ | 6.1¢ | 5.8¢ | $1.072M | 18.07M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 85851 | 6.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.1¢ | 335299 | 3 |
View Market Depth
| Last trade - 16.10pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
6.1¢ |
Change
0.001 ( 2.37 %) |
||||
| Open | High | Low | Volume | ||
| 5.9¢ | 6.1¢ | 5.8¢ | 7197252 | ||
| Last updated 15.59pm 07/06/2024 ? | |||||
| IMU (ASX) Chart |